BTK and non-small cell lung carcinoma: [23] Combining the previously reported biochemical activity of ibrutinib against wt EGFR and the fact that similar reactive cysteine residues are located at the same positions in EGFR and BTK, we performed a comprehensive comparison study of ibrutinib against NSCLC in vitro and in vivo.